BAM
LGND icon

Belpointe Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Belpointe Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-106
Closed -$7.8K – 2132
2023
Q1 		$7.8K Buy
106
+6
+6% +$427 ﹤0.01% 2840
2022
Q4 		$6.68K Buy
+100
New +$6.5K ﹤0.01% 2813
2020
Q1 		– Sell
-2,124
Closed -$138K – 715
2019
Q4 		$138K Sell
2,124
-160
-7% -$10.7K 0.02% 663
2019
Q3 		$142K Buy
+2,284
New +$143K 0.02% 574

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Belpointe Asset Management's LGND Position: Q2 2023 in Review

Belpointe Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 106 shares — an estimated $7.8K sold.

Belpointe Asset Management first reported a position in LGND in Q3 2019 and held it in 4 quarters. The position peaked at $142K in Q3 2019. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

  • Belpointe Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 106 Ligand Pharmaceuticals shares in Q2 2023, an estimated $7.8K.
  • Belpointe Asset Management first reported a position in Ligand Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Belpointe Asset Management's Ligand Pharmaceuticals position peaked at $142K in Q3 2019.
  • 204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.